CAH vs. BIIB

In the year-to-date period, CAH achieves a 21.09% return, which is significantly higher than BIIB's -39.71% return. Over the past 10 years, CAH has outperformed BIIB with an annualized return of 7.30%, while BIIB has yielded a comparatively lower -5.68% annualized return.

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

This table presents a comparison of risk-adjusted performance metrics for Cardinal Health, Inc. (CAH) and Biogen Inc. (BIIB). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

The current CAH Sharpe Ratio is 0.75, which is higher than the BIIB Sharpe Ratio of -1.25. The chart below compares the historical Sharpe Ratios of CAH and BIIB, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

CAH's dividend yield for the trailing twelve months is around 1.67%, while BIIB has not paid dividends to shareholders.

The maximum CAH drawdown since its inception was -61.68%, smaller than the maximum BIIB drawdown of -90.24%. Use the drawdown chart below to compare losses from any high point for CAH and BIIB. For additional features, visit the drawdowns tool.

Cardinal Health, Inc. (CAH) has a higher volatility of 10.48% compared to Biogen Inc. (BIIB) at 6.38%. This indicates that CAH's price experiences larger fluctuations and is considered to be riskier than BIIB based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

This section allows you to compare key financial metrics between Cardinal Health, Inc. and Biogen Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.